FDA orders clinical hold on Targeted Genetics trial

The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis. The hold came after one subject experienced a serious adverse event, but the company says there is insufficient information to draw conclusions as to the cause.

You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory